CA2810851C - Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide - Google Patents

Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide Download PDF

Info

Publication number
CA2810851C
CA2810851C CA2810851A CA2810851A CA2810851C CA 2810851 C CA2810851 C CA 2810851C CA 2810851 A CA2810851 A CA 2810851A CA 2810851 A CA2810851 A CA 2810851A CA 2810851 C CA2810851 C CA 2810851C
Authority
CA
Canada
Prior art keywords
polypeptide
isolated
hmg
biofilm
recombinant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2810851A
Other languages
English (en)
French (fr)
Other versions
CA2810851A1 (en
Inventor
Steven D. Goodman
Lauren O. Bakaletz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Nationwide Childrens Hospital Inc
Original Assignee
University of Southern California USC
Nationwide Childrens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC, Nationwide Childrens Hospital Inc filed Critical University of Southern California USC
Publication of CA2810851A1 publication Critical patent/CA2810851A1/en
Application granted granted Critical
Publication of CA2810851C publication Critical patent/CA2810851C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
CA2810851A 2010-09-09 2011-09-09 Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide Active CA2810851C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38137710P 2010-09-09 2010-09-09
US61/381,377 2010-09-09
PCT/US2011/051107 WO2012034090A1 (en) 2010-09-09 2011-09-09 Compositions and methods for the removal of biofilms

Publications (2)

Publication Number Publication Date
CA2810851A1 CA2810851A1 (en) 2012-03-15
CA2810851C true CA2810851C (en) 2022-08-02

Family

ID=44654515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2810851A Active CA2810851C (en) 2010-09-09 2011-09-09 Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide

Country Status (6)

Country Link
US (2) US20120128701A1 (enExample)
EP (1) EP2613797B1 (enExample)
JP (4) JP6012603B2 (enExample)
AU (1) AU2011299025B2 (enExample)
CA (1) CA2810851C (enExample)
WO (1) WO2012034090A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
SG183816A1 (en) * 2010-03-29 2012-10-30 Res Inst Nationwide Childrens Hospital Compositions and methods for the removal of biofilms
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
AU2014278037A1 (en) * 2013-06-13 2016-01-07 Ohio State Innovation Foundation Compositions and methods for the treatment of Burkholderia infections
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
AU2015227075A1 (en) 2014-03-06 2016-09-22 Ohio State Innovation Foundation Probiotic formulations and methods for use
WO2016154491A1 (en) * 2015-03-25 2016-09-29 Trellis Bioscience, Llc Binding moieties for biofilm remediation
WO2017011588A1 (en) 2015-07-14 2017-01-19 Research Institute At Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
CA2993009A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
PL3556378T3 (pl) 2017-01-27 2025-06-09 StemRIM Inc. Środek do leczenia kardiomiopatii, starego zawału mięśnia sercowego i przewlekłej niewydolności serca
AU2018236271B2 (en) * 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN118460462A (zh) 2017-12-01 2024-08-09 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
JP7235776B2 (ja) * 2018-06-12 2023-03-08 テルモ カーディオバスキュラー システムズ コーポレイション 心血管弁処置のための円形リトラクタ
JP6641420B2 (ja) 2018-06-12 2020-02-05 株式会社アマダホールディングス 分割金型の装着方法及びプレスブレーキ
WO2020072993A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
US12569524B2 (en) 2018-10-22 2026-03-10 Research Institute At Nationwide Children's Hospital Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state
EP3930735A1 (en) 2019-02-26 2022-01-05 The Regents of the University of Colorado, a body corporate Method and composition for treating gastrointestinal inflammatory disorders
KR20220016481A (ko) 2019-06-03 2022-02-09 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 패혈증 및 괴사성 장염 유도된 신경발달 결핍의 예방을 위한 프리바이오틱 제형
JP7627255B2 (ja) 2019-07-08 2025-02-05 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムを破壊するための抗体組成物
WO2025106896A1 (en) * 2023-11-17 2025-05-22 Rush University Medical Center Coating of medical and implant biomaterials with an anti-biofilm agent to prevent and treat infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US20050131222A1 (en) 1995-04-21 2005-06-16 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20020132753A1 (en) * 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
BR0209689A (pt) * 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
JP4511173B2 (ja) 2001-08-24 2010-07-28 マイジェニックス インコーポレイテッド 抗菌性および抗炎症性ペプチド
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20030099602A1 (en) 2001-10-25 2003-05-29 Levin Gilbert V. D-tagatose as an anti-biofilm agent
CA2493124C (en) 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
AU2003295653B2 (en) * 2002-11-20 2007-08-16 The Feinstein Institute Of Medical Research Use of HMGB polypeptides for increasing immune responses
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
US7297340B2 (en) 2003-01-07 2007-11-20 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
EP1592707A2 (en) * 2003-02-14 2005-11-09 Fondazione Centro San Raffaele Del Monte Tabor Hmgb1 modulator binding domain
CA2517899A1 (en) 2003-03-06 2004-09-16 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
WO2005093067A1 (ja) 2004-03-26 2005-10-06 Locomogene, Inc. シノビオリン遺伝子のプロモーターに対するデコイ核酸
WO2006083301A2 (en) * 2004-06-17 2006-08-10 Medimmune, Inc. Immunogenic compositions comprising hmgb1 polypeptides
EP1791566A4 (en) 2004-08-06 2008-07-16 Nat Jewish Med & Res Center PRODUCT AND METHOD FOR INHIBITING BIOFILM DEVELOPMENT
CN101132811B (zh) 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
US20060228384A1 (en) 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
CA2642264A1 (en) 2006-02-13 2007-08-30 Trustees Of Boston University Reca inhibitors with antibiotic activity, compositions and methods of use
NZ574758A (en) 2006-08-21 2012-03-30 Univ British Columbia Small cationic antimicrobial peptides
EP1980269A1 (en) 2007-04-13 2008-10-15 Katholieke Universiteit Leuven Prevention of staphylococcus biofilm formation
SG183816A1 (en) 2010-03-29 2012-10-30 Res Inst Nationwide Childrens Hospital Compositions and methods for the removal of biofilms
EP2613797B1 (en) * 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
AU2014278037A1 (en) 2013-06-13 2016-01-07 Ohio State Innovation Foundation Compositions and methods for the treatment of Burkholderia infections
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections

Also Published As

Publication number Publication date
JP2013542185A (ja) 2013-11-21
JP2017160265A (ja) 2017-09-14
US10595530B2 (en) 2020-03-24
JP6012603B2 (ja) 2016-10-25
AU2011299025A1 (en) 2013-03-21
US20160095316A1 (en) 2016-04-07
JP6420417B2 (ja) 2018-11-07
JP2018111731A (ja) 2018-07-19
US20120128701A1 (en) 2012-05-24
CA2810851A1 (en) 2012-03-15
AU2011299025B2 (en) 2015-07-09
WO2012034090A1 (en) 2012-03-15
JP2016000760A (ja) 2016-01-07
EP2613797B1 (en) 2015-11-04
EP2613797A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
US10595530B2 (en) Compositions and methods for the removal of biofilms
Nielubowicz et al. Host–pathogen interactions in urinary tract infection
JP4940479B2 (ja) マイコバクテリウム・ツベルクローシス融合蛋白質及びその応用
US12419944B2 (en) DNABII vaccines and antibodies with enhanced activity
Lu et al. Lactoferrin: a critical mediator of both host immune response and antimicrobial activity in response to streptococcal infections
JP2014512361A (ja) 病原性疾患における細菌ｍａｍポリペプチドの調節
JP2021035394A (ja) バイオフィルムの除去のためのペプチドおよび抗体
KR20080027877A (ko) 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
US20210340198A1 (en) Hmgb1 protein derivatives for the removal of biofilms
JP2025122021A (ja) 抗炎症剤
TW201138813A (en) Treatment or prevention of infection
EP0560969A1 (fr) Vaccin de sous-unite contre les infections a neisseriameningitidis et sous-unites correspondantes a l'etat purifie
US20210332095A1 (en) Infection-induced endothelial amyloid compositions as antimicrobials
FR2809960A1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
Ohalekwu Heat-stable enterotoxin B (STB) of Escherichia coli: structure, mechanism, and role in intestinal secretion, barrier dysfunctions and inflammation
do Nascimento Mil-Homens Burkholderia cenocepacia pathogenesis: unraveling the virulence functions of trimeric
Wu Identification and characterization of Porphyromonas gingivalis virulence genes using a pPGIVET system
Smith Development of Vaccines Against Uropathogenic Escherichia coli Toxins to Reduce Morbidity Associated with Urinary Tract Infections
Wang et al. Effects of ibeA deletion on the virulence and biofilm formation of an avian

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160909

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702